Please see full Summary of Product Characteristics for more details.

For full prescribing information please see the Summary of Product Characteristics.

Please see the Summary of Product Characteristics for a complete list of all possible side effects.

Please refer to Summary of Product Characteristics before prescribing.

For full details of these and other side-effects, please see the Summary of Product Characteristics, approved in your country.

Summary of Product Characteristics.

Summary of Product Characteristics Please find general information relating to Gemeprost Pessaries in this section.

These events should be monitored carefully, see Summary of Product Characteristics for information on appropriate management of these adverse events.

Sprycel Summary of Product Characteristics (from the European Medicines Agency website)

Entries are independently compiled by the MIMS editorial team based on the full Summary of Product Characteristics.

Please select the one you are interested in: Patient Information Leaflet Summary of Product Characteristics What is Anxiety?

The PIL is written by the manufacturing pharmaceutical company and is a patient friendly version of the Summary of Product Characteristics.

Summary of Product Characteristics Nilotinib (November 2007) Novartis AG (Europe)

In case of positive Opinions, the Summary of Product Characteristics (SPC), which is the information destined for health professionals, will be attached.

Unfortunately we do not have Summary of Product Characteristics or Patient Information Leaflet text available on-line for Lactulose Solution 500ml.

Box 1 Summary of Product Characteristics Combination antiretroviral therapy, including regimens containing a protease inhibitor, is associated with redistribution of body fat in some patients.

In the European Summary of Product Characteristics, the recommendation is that physicians not administer drotrecogin alfa (activated) to patients with platelet counts of 30,000/mm 3or less.

Doralese Tablets These are now named Doralese Tiltab tablets in line with the company's Summary of Product Characteristics.

The bioavailability of the commercial tablet is 0.1% while that of the nasal spray is 3-5% according to the SPC (Summary of Product Characteristics).

(see SmPC) Almotriptan has proved to have an adverse effects profile similar to placebo when used following the Summary of Product Characteristics instructions (see references).

Severe thrombocytopenia is included as a 'warning' in the US Package Insert and as a 'contraindication' in the European Summary of Product Characteristics.

As a result, there are discrepancies and variations in the Summary of Product Characteristics between countries resulting in the inability of generic manufacturers to apply one formula throughout Europe.

At the time the Summary of Product Characteristics for paroxetine in Europe said that its use in children was "not recommended as safety and efficacy have not been established in this population."

The Summary of Product Characteristics (SmPC) has the full prescribing information, including the safety and efficacy profile of PIXUVRI in the approved indication.

Additional side effect information is provided in the Ortho Evra label information and the Evra Summary of Product Characteristics (SPC) and PIL.